FluoroPharma CEO Provides Shareholders With a "State of the Union" Communication

BOSTON, Dec. 13, 2011 (GLOBE NEWSWIRE) -- FluoroPharma Medical, Inc. (OTCBB:FPMI), a company specializing in the development of breakthrough diagnostic imaging products that utilize positron emission tomography (PET) technology to detect and assess pathology before clinical manifestation of diseases, announced today the release of a company overview as presented by FluoroPharma's President and CEO, Thijs Spoor. This "State of the Union" address serves to provide shareholders with a complete picture of the company, its evolution and future potential.